Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001171843-20-003557
Filing Date
2020-05-11
Accepted
2020-05-08 17:41:36
Documents
56
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q f10q_050820p.htm 10-Q 625076
2 EXHIBIT 10.1 exh_101.htm EX-10.1 97211
3 EXHIBIT 10.2 exh_102.htm EX-10.2 83644
4 EXHIBIT 31.1 exh_311.htm EX-31.1 8527
5 EXHIBIT 31.2 exh_312.htm EX-31.2 8641
6 EXHIBIT 32.1 exh_321.htm EX-32.1 3661
7 EXHIBIT 32.2 exh_322.htm EX-32.2 3655
14 GRAPHIC logo2.jpg GRAPHIC 1255
15 GRAPHIC logo.jpg GRAPHIC 2954
16 GRAPHIC logo3.jpg GRAPHIC 3051
17 GRAPHIC logo4.jpg GRAPHIC 1015
  Complete submission text file 0001171843-20-003557.txt   4341152

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE FILE bcrx-20200331.xml EX-101.INS 713911
9 XBRL SCHEMA FILE bcrx-20200331.xsd EX-101.SCH 50544
10 XBRL CALCULATION FILE bcrx-20200331_cal.xml EX-101.CAL 32562
11 XBRL DEFINITION FILE bcrx-20200331_def.xml EX-101.DEF 367517
12 XBRL LABEL FILE bcrx-20200331_lab.xml EX-101.LAB 344611
13 XBRL PRESENTATION FILE bcrx-20200331_pre.xml EX-101.PRE 379507
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 20861965
SIC: 2836 Biological Products, (No Diagnostic Substances)